Treatment effect of alirocumab according to age group, smoking status, and hypertension: pooled analysis from 10 randomized ODYSSEY studies (2019)
- Authors:
- Autor USP: SANTOS FILHO, RAUL DIAS DOS - FM
- Unidade: FM
- DOI: 10.1016/j.jacl.2019.06.006
- Subjects: ENZIMAS PROTEOLÍTICAS; TABAGISMO; HIPERTENSÃO; FATORES ETÁRIOS; LIPOPROTEÍNAS; HIPERCOLESTEROLEMIA
- Agências de fomento:
- Language: Inglês
- Imprenta:
- Source:
- Título do periódico: Journal of clinical lipidology
- ISSN: 1933-2874
- Volume/Número/Paginação/Ano: v. 13, n. 5, p. 735-743, 2019
- Este periódico é de assinatura
- Este artigo é de acesso aberto
- URL de acesso aberto
- Cor do Acesso Aberto: hybrid
- Licença: cc-by-nc-nd
-
ABNT
RAAL, Frederick J et al. Treatment effect of alirocumab according to age group, smoking status, and hypertension: pooled analysis from 10 randomized ODYSSEY studies. Journal of clinical lipidology, v. 13, n. 5, p. 735-743, 2019Tradução . . Disponível em: https://doi.org/10.1016/j.jacl.2019.06.006. Acesso em: 27 abr. 2024. -
APA
Raal, F. J., Tuomilehto, J., Sposito, A. C., Fonseca, F. A., Averna, M., Farnier, M., et al. (2019). Treatment effect of alirocumab according to age group, smoking status, and hypertension: pooled analysis from 10 randomized ODYSSEY studies. Journal of clinical lipidology, 13( 5), 735-743. doi:10.1016/j.jacl.2019.06.006 -
NLM
Raal FJ, Tuomilehto J, Sposito AC, Fonseca FA, Averna M, Farnier M, Santos Filho RD dos, Ferdinand KC, Wright RS, Navarese EP. Treatment effect of alirocumab according to age group, smoking status, and hypertension: pooled analysis from 10 randomized ODYSSEY studies [Internet]. Journal of clinical lipidology. 2019 ; 13( 5): 735-743.[citado 2024 abr. 27 ] Available from: https://doi.org/10.1016/j.jacl.2019.06.006 -
Vancouver
Raal FJ, Tuomilehto J, Sposito AC, Fonseca FA, Averna M, Farnier M, Santos Filho RD dos, Ferdinand KC, Wright RS, Navarese EP. Treatment effect of alirocumab according to age group, smoking status, and hypertension: pooled analysis from 10 randomized ODYSSEY studies [Internet]. Journal of clinical lipidology. 2019 ; 13( 5): 735-743.[citado 2024 abr. 27 ] Available from: https://doi.org/10.1016/j.jacl.2019.06.006 - Foi com muita satisfação que recebemos o convite dos ...[Apresentação]
- Relation of Uric Acid to Serum Levels of High-Sensitivity C-Reactive Protein, Triglycerides, and High-Density Lipoprotein Cholesterol and to Hepatic Steatosis
- Homozygous familial hypercholesterolemia: Current perspectives on diagnosis and treatment
- Elevated uric acid, the metabolic syndrome and cardiovascular disease [Editorial]: cause, consequence, or just a not so innocent bystander?
- Lipid-lowering treatment for homozygous familial hypercholesterolaemia [Carta]
- Statin Use Is Not Associated With Presence of and Severity of Nonalcoholic Fatty Liver Disease
- A systematic review: Burden and severity of subclinical cardiovascular disease among those with nonalcoholic fatty liver; Should we care?
- Relation of Hepatic Steatosis to Atherogenic Dyslipidemia
- Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society
- Cigarette smoking worsens systemic inflammation in persons with metabolic syndrome
Informações sobre o DOI: 10.1016/j.jacl.2019.06.006 (Fonte: oaDOI API)
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
